Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Imine. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN114349684B reveals a one-pot Pd-catalyzed route for benzo[c,d]indole imines, offering safer alternatives to mercury-based methods for pharmaceutical intermediate manufacturing.
Patent CN110467613B reveals a mild nickel-catalyzed route for isoindolinones, offering significant cost reduction in API manufacturing and enhanced supply chain reliability.
Discover the novel Pd-catalyzed synthesis of polysubstituted ketene imines from patent CN110590717B. A mild, efficient route for high-purity pharmaceutical intermediates.
Novel binaphthyl phosphoric acid catalyzed synthesis of isoindolinone imines. High yield, mild conditions, suitable for commercial scale-up in pharmaceutical manufacturing.
Novel copper-catalyzed cyanation method offers mild conditions and high yields for anti-inflammatory intermediates, ensuring reliable supply chain stability.
Patent CN115353482B reveals metal-free synthesis for high-purity spirocyclic intermediates. Enables cost reduction and scalable supply chain for pharmaceutical manufacturing.
Patent CN118878452B reveals novel antitumor compound synthesis. Offers mild conditions and high yield for pharmaceutical intermediate supply chains. Enables cost reduction in API manufacturing.
Novel metal-free synthesis method for trifluoromethyl selenium azaspiro compounds offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing globally.
Novel metal-free synthesis of trifluoromethyl 1,2,4-triazines via [3+3] cycloaddition. Cost-effective, scalable route for pharma intermediates.
Patent CN113072470A reveals a mild Cu-catalyzed synthesis for N-acetonitrile bis-benzenesulfonylimine derivatives, offering cost reduction in pharmaceutical intermediate manufacturing.
Novel iodine-promoted method for 3,4,5-trisubstituted 1,2,4-triazoles offers cost-effective, scalable routes for pharmaceutical intermediates without heavy metals.
Patent CN118878452B reveals mild synthesis for antitumor intermediates. Offers cost reduction in pharmaceutical intermediates manufacturing and supply chain reliability.
Novel iron-catalyzed asymmetric hydrogenation technology using chiral quinoline imidazoline ligands. Reduces noble metal dependency for high-purity pharmaceutical intermediates.
Novel metal-free synthesis of trifluoromethyl 1,2,4-triazines via [3+3] cycloaddition. Cost-effective, scalable route for pharma intermediates.
Novel Pd-catalyzed route for complex ketene imines via enynone insertion. Mild conditions, high atom economy. Ideal for API intermediates and fine chemical manufacturing scale-up.
Novel metal-free synthesis patent CN115353482B offers cost reduction and supply chain reliability for high-purity pharmaceutical intermediates manufacturing.
Novel iodine-promoted route for 3,4,5-trisubstituted 1,2,4-triazoles offers cost-effective, scalable production for global API manufacturers.
Patent CN110105404A reveals a stable ruthenium catalyst enabling green imine synthesis. This technology offers substantial cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN113105402A details a metal-free iodine-catalyzed route for 3,4,5-trisubstituted 1,2,4-triazoles, offering significant cost reduction in API manufacturing and scalable production.
Patent CN118126005B reveals metal-free synthesis for high-purity pharmaceutical intermediates. Achieve cost reduction and supply chain reliability with scalable air-atmosphere reactions.